RE:RE:RE:RE:RE:RE:bepando - PLI cash needs
Plilong: have a listen to Q3 ( I think )conference call. PL addresses cash burn rate in response to a question from one of the analysts. I seem to recall a comment from PL that 2015 spend on drug development R+D will be less than 2014 as much of the cost will have been spent ie the R+d spend is not linear. I suppose the caveate here is whether the drug pipeline continues to expand.
Coyote13